CLINICAL TRIALS PROFILE FOR VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

All Clinical Trials for VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00057356 ↗	Safety and Efficacy Study of YM087 (Conivaptan) in Patients With Acute Decompensated Heart Failure	Completed	Cumberland Pharmaceuticals	Phase 2	2002-11-01	This is a randomized, double-blind, placebo-controlled, dose ranging pilot study to examine the effects of conivaptan in patients with acute decompensated heart failure.
NCT00379847 ↗	An Open-Label Study of YM087 (Conivaptan) in Patients With Euvolemic or Hypervolemic Hyponatremia	Completed	Cumberland Pharmaceuticals	Phase 3	2004-02-01	This study will investigate the application of a vasopressin antagonist in the treatment of hyponatremia most likely caused by inappropriate AVP secretion. The population studied will include patients with euvolemic or hypervolemic hyponatremia.
NCT00435591 ↗	A Study of Multiple Dosing Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia	Completed	Cumberland Pharmaceuticals	Phase 4	2007-01-01	The study will evaluate the effectiveness and safety of multiple dosing regimens of IV conivaptan in subjects with euvolemic or hypervolemic hyponatremia
NCT00478192 ↗	Study of Efficacy & Safety for 3 Infusion Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia	Completed	Cumberland Pharmaceuticals	Phase 3	2007-04-01	The study is designed to assess the efficacy and safety of multiple infusions of conivaptan in subjects with euvolemic or hypervolemic hyponatremia
NCT00684164 ↗	Safety and Efficacy of Conivaptan for the Correction of Hyponatremia in Neurological Patients	Withdrawn	Astellas Pharma Inc	Phase 3	2008-05-01	Low sodium levels (hyponatremia) are a frequent occurrence in medically ill patients, and in particular those with neurological injury. Hyponatremia has been associated with worse outcome, problems with memory and concentration and impaired balance. Standard treatment for low sodium (salt) levels is to give the patient a salt containing solution thru a catheter (small flexible tube) in a vein in the arm or leg. One of the major complications of this treatment is excess body fluid which may cause heart problems or accumulation of fluid in the lungs and may require additional medications to remove extra water from the body. FDA approval has recently been granted for a new drug - Conivaptan - for use in hyponatremic conditions. Conivaptan works by excreting free water from the body and thereby produce concurrent rise in serum sodium concentrations. Conivaptan has not been evaluated specifically in patients with brain injuries. The primary objective of this study is to demonstrate the safety and efficacy of intravenous Conivaptan for the treatment of hyponatremia in patients with brain injury. If effective, Conivaptan may represent a safe treatment option.

Clinical Trial Conditions for VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

Condition Name

Condition Name for VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER
Intervention	Trials
Hyponatremia	8
Heart Failure	3
Liver Disease	2
Cerebral Edema	2

Condition MeSH

Condition MeSH for VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER
Intervention	Trials
Hyponatremia	8
Heart Failure	4
Liver Diseases	2
Edema	2

Clinical Trial Locations for VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

Trials by Country

Trials by Country for VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER
Location	Trials
United States	48
Israel	2
India	2
South Africa	1
Denmark	1

Trials by US State

Trials by US State for VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER
Location	Trials
South Carolina	4
New York	4
Florida	4
California	4
Colorado	3

Clinical Trial Progress for VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

Clinical Trial Phase

Clinical Trial Phase for VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Phase 4	4
Phase 3	4
Phase 2	2

Clinical Trial Status

Clinical Trial Status for VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Completed	10
Withdrawn	3
Terminated	2

Clinical Trial Sponsors for VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

Sponsor Name

Sponsor Name for VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER
Sponsor	Trials
Cumberland Pharmaceuticals	8
Astellas Pharma Inc	3
Northwestern University	1

Sponsor Type

Sponsor Type for VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER
Sponsor	Trials
Industry	12
Other	9

VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER Market Analysis and Financial Projection

Last updated: May 9, 2026

VAPRISOL (Desmopressin Acetate) in 5% Dextrose in Plastic Container: Clinical Trials Update, Market Analysis, and Projection

What is the product and where does it fit clinically?

VAPRISOL is a desmopressin acetate formulation presented as desmopressin in 5% dextrose in plastic container. Clinically, desmopressin is used for conditions where patients need antidiuretic activity (commonly central diabetes insipidus and nocturnal enuresis in approved populations). The key market reality for this specific presentation is that it behaves like an infusion- or administration-format product tied to supply chain execution, formulary access, and administration workflows rather than an innovation-driven drug class.

Competitive set for demand capture

• Other desmopressin acetate products in liquid and non-liquid formats (tablets, nasal sprays, and other parenteral/infusion presentations, depending on country).
• Therapeutic alternatives to desmopressin by indication (less directly interchangeable, but competing for same patient needs in practice).

What is the clinical trials update for VAPRISOL in 5% dextrose (plastic container)?

No complete, source-backed clinical trial pipeline updates specific to VAPRISOL in 5% dextrose in plastic container can be produced from the information available in this prompt. A “clinical trials update” that separates:

• product-specific formulation and packaging,
• sponsor and trial phase,
• indication-level outcomes,
• timing (start/completion/primary results), requires verifiable trial registry or publication entries keyed to this exact product configuration.

Therefore, no trial-stage or outcome statements are presented.

---

What does the market look like for VAPRISOL 5% dextrose in plastic container?

How is demand typically formed for this category?

For desmopressin in injectable/infusion-compatible formats, procurement demand is driven by:

• inpatient and peri-procedural use patterns where infusion-ready dosing is preferred,
• hospital pharmacy formulary rules and substitution policies,
• contract availability and logistics reliability for plastic container supply,
• therapeutic persistence in chronic indications (where patients remain on therapy).

Market segmentation that matters for pricing and volume

Demand splits by:

• Setting: hospital (procurement-led) versus outpatient clinics (contract-led).
• Indication mix: central diabetes insipidus tends to be chronic; nocturnal enuresis is often intermittent/pediatric and can be supply-sensitive.
• Form factor preference: infusion-ready presentations win when dosing workflow favors liquid/parenteral administration.

Why this specific presentation changes the commercial equation

Even when the active ingredient is the same, market behavior differs by:

• packaging/handling: plastic container logistics can improve shelf/handling compatibility versus alternatives in some systems,
• workflow fit: administration route availability affects how quickly the product can be deployed.

Commercial risk profile

Key risks for this category are usually operational rather than scientific:

• supply continuity and contract wins dominate volume more than incremental clinical differentiation,
• regulatory and labeling consistency constrain substitution decisions,
• pricing pressure is common where generics and alternate formulations exist.

Market data (units, value, forecast baseline, and share) cannot be quantified from the prompt alone. A numeric projection requires at minimum: region coverage, baseline sales, and competitor counts.

---

What market projection is feasible for this product?

A defensible market projection for VAPRISOL in 5% dextrose in plastic container requires:

• historical sales baseline (by geography),
• expected entry/exit of competing desmopressin formulations,
• formulary and contracting dynamics,
• regulatory status (active, discontinued, or reformulated).

No such quantitative inputs are available in the provided prompt, so no numeric forecast can be issued.

---

What business actions should be prioritized given the constraints of this product category?

For R&D and life-cycle planning

• Validate whether any development is formulation- or delivery-route focused (not just active ingredient). In this segment, packaging and administration method can drive adoption in hospital contracts.
• Confirm whether future differentiation would be usability and stability improvements rather than new pharmacology.

For investment diligence

• Treat this as a manufacturing and access story. Diligence should target supply reliability, batch consistency, and ability to maintain contracted availability.
• Identify whether substitution risk comes from other desmopressin acetate products with equivalent dosing and route.

For commercial strategy

• Align contracting strategy to hospital pharmacy buyer criteria: procurement reliability and workflow compatibility.
• Monitor competitive switch-points: whenever contracts renew, substitution and rebidding occur.

---

Key Takeaways

• VAPRISOL is desmopressin acetate delivered as 5% dextrose in a plastic container, placing its commercial performance in the category of administration-format, supply-and-access-driven pharmaceutical demand.
• A product-specific clinical trials update for this exact formulation cannot be stated from the information provided.
• A numeric market analysis and projection cannot be produced without baseline sales, geography, and competitor/configuration mapping.
• The dominant commercial levers for this segment are hospital contracting, supply continuity, and format usability, not new clinical differentiation.

---

FAQs

1) Does “VAPRISOL in 5% dextrose in plastic container” change the active ingredient’s pharmacology?

No, the clinical pharmacology is determined by desmopressin acetate; the container and diluent mainly affect delivery and handling.

2) What drives hospital adoption for this type of product?

Availability under contract, workflow fit for infusion-ready administration, and consistent supply reliability.

3) Are clinical trials for this product always needed to maintain market presence?

Often not. Lifecycle maintenance can depend more on manufacturing, labeling, and supply continuity than on new efficacy trials, depending on regulatory requirements.

4) How do competing products typically affect pricing?

Comparable desmopressin offerings in alternative formats can drive substitution and pricing pressure in contract rebids.

5) What is the most important metric for forecasting demand here?

Contracted volume and supply continuity in the target settings (hospital systems), rather than new-patient growth typical of novel therapeutics.

---

References

[1] No citable sources were provided or retrievable from the prompt content, so no APA citations can be listed.